XSPRAY.ST实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 23:13):

Stats
今日成交量	15 615.00
平均成交量	15 771.00
市值	1.26B
EPS	SEK-1.588 ( 2023-11-08 )
下一个收益日期	( SEK0 ) 2024-05-21
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-5.98
ATR14	SEK0.0890 (0.22%)

Xspray Pharma AB (publ) 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Xspray Pharma AB (publ) 相关性 - 货币/商品

-0.07
( neutral )

-0.29
( neutral )

0.00
( neutral )

-0.12
( neutral )

-0.33
( neutral )

-0.35
( neutral )

Xspray Pharma AB (publ) 财务报表

Annual	2023
营收:	SEK0
毛利润:	SEK-9.19M (0.00 %)
EPS:	SEK-6.76

FY	2023
营收:	SEK0
毛利润:	SEK-9.19M (0.00 %)
EPS:	SEK-6.76

FY	2022
营收:	SEK0
毛利润:	SEK-9.53M (0.00 %)
EPS:	SEK-6.13

FY	2021
营收:	SEK0.00
毛利润:	SEK0.00 (0.00 %)
EPS:	SEK-5.03

Financial Reports:

No articles found.

Xspray Pharma AB (publ)

Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo for the treatment of chronic myeloid leukemia; HyNap-Sora for the treatment of renal cancer and liver cancer, as well as several forms of thyroid cancer; and HyNap-Dasa for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is based in Solna, Sweden.